Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19.

ABSTRACT:

Background

Patients with end-stage kidney disease (ESKD) are highly susceptible to coronavirus disease 2019 (COVID-19) infection and its complications. Remdesivir has improved outcomes in COVID-19 patients but its use has been limited among ESKD patients due to insufficient data regarding safety outcomes. We sought to evaluate the safety of remdesivir among dialysis patients hospitalized with COVID-19.

Methods

This retrospective cohort study was conducted among patients age ≥18 years on maintenance dialysis and hospitalized with COVID-19 between 1 May 2020 and 31 January 2021 within an integrated health system who were treated or not treated with remdesivir. The primary outcome was 30-day all-cause mortality. Secondary outcomes were intensive care unit (ICU) stay, and transa

SUBMITTER: Zaki KE 

PROVIDER: S-EPMC9452122 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature